ACAD - ACADIA Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
7.92B
Enterprise Value 3
7.1B
Trailing P/E
N/A
Forward P/E 1
-39.54
PEG Ratio (5 yr expected) 1
-1.18
Price/Sales (ttm)
26.36
Price/Book (mrq)
11.45
Enterprise Value/Revenue 3
23.65
Enterprise Value/EBITDA 6
-27.90

Trading Information

Stock Price History

Beta (3Y Monthly) 2.82
52-Week Change 3168.80%
S&P500 52-Week Change 318.19%
52 Week High 353.70
52 Week Low 314.01
50-Day Moving Average 344.33
200-Day Moving Average 333.60

Share Statistics

Avg Vol (3 month) 32.27M
Avg Vol (10 day) 32.35M
Shares Outstanding 5154.02M
Float 112.89M
% Held by Insiders 10.30%
% Held by Institutions 198.72%
Shares Short (Nov 15, 2019) 410.67M
Short Ratio (Nov 15, 2019) 47.68
Short % of Float (Nov 15, 2019) 412.91%
Short % of Shares Outstanding (Nov 15, 2019) 46.92%
Shares Short (prior month Oct 15, 2019) 411.12M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin -82.48%
Operating Margin (ttm)-85.71%

Management Effectiveness

Return on Assets (ttm)-31.18%
Return on Equity (ttm)-54.28%

Income Statement

Revenue (ttm)300.32M
Revenue Per Share (ttm)2.12
Quarterly Revenue Growth (yoy)62.20%
Gross Profit (ttm)18.31M
EBITDA -254.51M
Net Income Avi to Common (ttm)-247.72M
Diluted EPS (ttm)-1.75
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)683.85M
Total Cash Per Share (mrq)4.44
Total Debt (mrq)10.27M
Total Debt/Equity (mrq)1.49
Current Ratio (mrq)10.96
Book Value Per Share (mrq)4.49

Cash Flow Statement

Operating Cash Flow (ttm)-160.5M
Levered Free Cash Flow (ttm)-73.02M